Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

National value-based pricing negotiation for oncology drugs — lessons from China

Between 2016 and 2022, 83 previously approved oncology drugs were covered and reimbursed in China through a value-based pricing negotiation programme, which resulted in substantial price cuts but did not improve the correlation between drug cost and clinical benefit. Herein, we call for an improved, transparent value-based pricing model to better account for high-value innovation in oncology drugs.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Effect of value-based pricing negotiation on the price of oncology drugs in China.


  1. Barrios, C. et al. Barriers in access to oncology drugs - a global crisis. Nat. Rev. Clin. Oncol. 20, 7–15 (2023).

    Article  CAS  PubMed  Google Scholar 

  2. Cherny, N. I. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed? Nat. Rev. Clin. Oncol. 19, 486–492 (2022).

    Article  PubMed  Google Scholar 

  3. Neumann, P. J., Cohen, J. T. & Ollendorf, D. A. The Right Price: A Value-Based Prescription for Drug Costs (Oxford Univ. Press, 2021).

  4. Cai, L. et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study. J. Glob. Health 12, 11016 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Li, H. et al. Recent pricing negotiations on innovative medicines pilot in China: experiences, implications, and suggestions. Value Health Reg. Issues 15, 133–137 (2018).

    Article  PubMed  Google Scholar 

  6. Tang, M., Song, P. & He, J. Progress on drug pricing negotiations in China. Biosci. Trends 13, 464–468 (2019).

    Article  PubMed  Google Scholar 

  7. Zhang, Y. et al. Prices and clinical benefit of national price-negotiated anticancer medicines in China. PharmacoEconomics 40, 715–724 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jommi, C., Armeni, P., Costa, F., Bertolani, A. & Otto, M. Implementation of value-based pricing for medicines. Clin. Ther. 42, 15–24 (2020).

    Article  PubMed  Google Scholar 

  9. Zhang, Y., Wagner, A. K. & Guan, X. Newly approved cancer drugs in China - innovation and clinical benefit. Nat. Rev. Clin. Oncol. 20, 135–136 (2023).

    Article  PubMed  Google Scholar 

  10. Yuan, J., Lu, Z. K., Xiong, X. & Jiang, B. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob. Health 6, e005519 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

Download references


The authors thank J. Bin (Peking University) for insightful suggestions for this project.

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Jing Yuan or Z. Kevin Lu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, J., Li, M. & Lu, Z.K. National value-based pricing negotiation for oncology drugs — lessons from China. Nat Rev Clin Oncol (2023).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer